Marcain (Bupivacaine Hydrochloride)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing the rapid influx of sodium that is required for depolarisation. By inhibiting nerve impulse generation and propagation, it creates a reversible loss of sensation and motor function in the targeted area.

The dose of Marcain is determined by the prescribing clinician based on the type of procedure, patient weight, and the desired depth and duration of anaesthesia. Dosage recommendations are provided in the product’s prescribing information and must be individualised for each patient.

Safety data for bupivacaine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Marcain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Both Marcain (bupivacaine) and lidocaine are local anaesthetics, but bupivacaine has a longer duration of action and a higher potency, making it suitable for procedures requiring prolonged analgesia. Lidocaine acts faster but wears off more quickly, and it carries a lower risk of cardiotoxicity at equivalent doses.

Marcain should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture, and avoid freezing. Inspect the vial for particulate matter before use and discard any product that appears discoloured or compromised.

Marcain is administered by a qualified healthcare professional via epidural injection, peripheral nerve block, or direct infiltration of the surgical site. The solution is injected using sterile technique, and the volume is titrated to achieve the desired level of anaesthesia while monitoring the patient’s vital signs.

The most serious risks include cardiac arrhythmias, severe hypotension, central nervous system toxicity such as seizures, and respiratory depression. Early recognition of symptoms and immediate supportive measures are essential to mitigate these potentially life‑threatening complications.

Marcain should be avoided in patients with known hypersensitivity to bupivacaine or other amide‑type local anaesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or significant liver disease that may impair drug metabolism. Contra‑indications must be confirmed by the treating physician.